Innoviva Quarterly Cash Flow Statement
NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Innoviva free cash flow
In the quarter ended Jun 30, 2026, Innoviva generated $52.0 million of operating cash flow and spent $429,000 on capital expenditures. That left free cash flow of $51.5 million, a free-cash-flow margin of 43.1% of revenue. Free cash flow was up 16.9% from the prior year's $44.1 million.
Innoviva returned $31.1 million to shareholders through share repurchases, equal to 60% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Innoviva cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -83.42M | 186.59M | 164.15M | 89.91M | 63.69M | -46.58M | 20.33M | 1.21M | -34.69M | 36.53M | 61.53M | 82.05M |
| Net Income growth (YoY) | -230.98% | — | +707.36% | +7312.04% | — | -227.52% | -66.96% | -98.52% | -2809.77% | +4.78% | — | -64.23% |
| Stock-Based Compensation | 4.74M | 2.57M | 2.50M | 2.38M | 2.42M | 2.15M | 1.67M | 1.60M | 1.64M | 1.46M | 1.28M | 1.44M |
| Change in Working Capital | -8.04M | -17.55M | -11.30M | -7.36M | -2.48M | -7.25M | -24.44M | -175.00K | -19.74M | -8.27M | -14.43M | 5.36M |
| Operating Cash Flow | 51.97M | 35.28M | 54.51M | 49.73M | 44.07M | 48.62M | 59.24M | 48.69M | 43.72M | 37.05M | 33.26M | 43.94M |
| Capital Expenditures | -429.00K | -492.00K | -10.00K | -1.12M | 0 | 0 | 0 | -270.00K | 0 | 0 | -151.00K | -227.00K |
| Investing Cash Flow | -55.26M | 37.01M | 23.64M | 18.41M | 33.12M | -34.67M | -15.48M | -5.27M | 0 | -43.04M | -5.15M | -25.89M |
| Share Repurchases | -31.07M | -20.25M | -4.53M | 0 | 0 | 0 | 0 | 0 | -5.21M | -9.57M | -14.64M | -11.07M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | -29.41M | -20.15M | -3.72M | 10.84M | 1.25M | 183.00K | 573.00K | 211.00K | -5.07M | -9.16M | -14.59M | -11.08M |
| Net Change in Cash | -32.70M | 52.14M | 74.43M | 78.98M | 78.44M | 14.13M | 44.33M | 43.63M | 38.65M | -15.16M | 13.52M | 6.97M |
| Free Cash Flow | 51.54M | 34.79M | 54.50M | 48.61M | 44.07M | 48.62M | 59.24M | 48.42M | 43.72M | 37.05M | 33.10M | 43.72M |
This table shows 12 quarterly periods of Innoviva's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INVA's reporting calendar. What is a cash flow statement?